• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Cancer investigation

    Cancer investigation

    JournalISSN 0735-7907eISSN 1532-4192中科院 医学 4区

    年发文量

    研究主题

    论文(4238)

    排序
    1Ctdna Positivity is Not a Treatment Indication: Defining the Actionability Threshold for Molecular Residual Disease.
    Jian Zheng,Yong Guo
    2026
    引用
    AI阅读
    加入学术空间
    2The Risk of Hyperglycemia with PI3K Inhibitors in Cancer Patients-A Meta-Analysis
    Zhan Rong,Shenhong Wu

    Phosphatidylinositol 3-kinase (PI3K) inhibitors are a promising class of targeted oncologic therapies but metabolic toxicities, particularly hyperglycemia, limit their use. We conducted a meta-analysis of phase II/III randomized controlled trials to quantify the incidence and relative risk (RR) of hyperglycemia associated with PI3K inhibition in cancer patients. A systematic search of PubMed through August 2025 identified 16 eligible trials, comprising approximately 5,000 patients. Among patients treated with PI3K inhibitors, the summary incidence of all-grade hyperglycemia was 44.4% (95% CI: 33.3-55.5%), while high-grade hyperglycemia occurred in 18.6% (95% CI: 9.7-27.6%). PI3K inhibitor was associated with an increased risk of hyperglycemia with an RR of 3.43 (95% CI: 2.42-4.87, p < 0.001) for all-grade events and 9.79 (95% CI: 5.77-16.62, p < 0.001) for high-grade events. Subgroup analysis showed that cancer type significantly moderated the incidence of high-grade hyperglycemia (p = 0.01). Subgroup analyses also showed significant variation among PI3K inhibitor subtypes (p < 0.01), with PI3K alpha-selective inhibitors conferring the greatest relative risk, particularly for severe hyperglycemia, whereas dual PI3K/mTOR inhibitors showed comparatively lower risk. These findings have demonstrated that PI3K inhibitors are associated with a significantly increased risk of hyperglycemia. Proactive monitoring and early intervention are essential to mitigate adverse outcomes and optimize therapeutic benefit.

    2026
    引用
    AI阅读
    加入学术空间
    3Ecosystem Determinants of Therapeutic Resistance in Pancreatic Cancer: Implications for Precision Oncology
    Aliasgar F. Shahiwala

    Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal despite advances in systemic and biomarker-directed therapy. Treatment resistance reflects not only tumor genotype but also desmoplasia, vascular dysfunction, immune suppression, metabolic adaptation, and evolutionary plasticity. This review integrates signaling dependency, ecosystem architecture, and adaptive evolution into an ecosystem-adaptive framework to explain therapeutic failure in PDAC and proposes four candidate ecosystem states: desmoplastic exclusion, myeloid dominance, hypoxic-metabolic adaptation, and immune-interface organization. These dynamic states may influence therapeutic exposure and resistance beyond conventional molecular classification. Prospective validation could support biomarker development, therapeutic stratification, rational treatment combinations, and treatment sequencing in pancreatic cancer.

    2026
    引用
    AI阅读
    加入学术空间
    4The Coagulation–Immune Axis in Oral Squamous Cell Carcinoma: Mechanisms, Prognostic Significance, and Therapeutic Opportunities
    Lianzhen Chang, Yugang Sun, Yan Wang, Min Liu, Wenxiang Qian, Jing Sun, Xiao Luan, Qingmei Zhou

    Oral squamous cell carcinoma (OSCC) develops in a microbe-rich, injury-prone mucosa in which coagulation, inflammation, and tissue repair are closely coupled. Tumor and host cells can activate tissue factor-thrombin signaling, platelets, fibrin turnover, extracellular vesicles, and neutrophil extracellular traps, thereby reshaping myeloid-cell recruitment, cytotoxic immunity, angiogenesis, and invasion. However, local procoagulant biology does not necessarily predict systemic venous thromboembolism. We therefore organize the evidence using a compartmentalized immunothrombosis model that distinguishes intratumoral coagulation-immune remodeling, systemic thrombosis, and treatment-dependent perioperative events. Direct OSCC studies support several components of this network, but much of the evidence linking coagulation to immune escape and treatment response remains preclinical or extrapolated from other tumors. Circulating D-dimer, fibrinogen, platelet indices, and inflammatory ratios show prognostic associations, yet their incremental value beyond established clinicopathologic factors has not been established. Anticoagulant, antiplatelet, protease-activated receptor, podoplanin-CLEC-2, fibrinolytic, and NET-directed strategies are biologically plausible but should not be used as OSCC treatment without a standard indication or clinical trial. Future studies should pair longitudinal blood measurements with spatial tumor profiling and match interventions to a verified mechanism, anatomical compartment, and safe treatment window.

    2026
    引用
    AI阅读
    加入学术空间
    5SLC9A3R1 Promotes Bladder Cancer Progression Through Regulation of Malignant Phenotypes: Integrated Bioinformatics Analysis and Experimental Validation
    Yimin Wang, Xiaoxiang Wu, Chong Shu, Tong Bao
    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 4238 篇论文

    高被引作者

    作者引用发文
    LA JONES69351
    Wendy J Levin69351
    DE KEITH69351
    MF PRESS69351
    J A Udove69351
    Dennis J. Slamon69351
    Steven G Wong69351
    Stuart Grossman9549
    Alberto Gabizon8012
    John Nemunaitis8008

    高产作者

    作者引用发文
    Gary Herbert Lyman29635
    Nicole M Kuderer13322
    Alfred I. Neugut34718
    Dawn L Hershman30717
    Maurie Markman9616
    Jacob Lokich16615
    Howard A. Skip Burris III30511
    Wright Jason D17611
    Janice P. Dutcher21810
    Cl Bennett41010

    相关期刊

    American journal of clinical oncology
    Expert review of anticancer therapy
    World journal of clinical oncology
    Cancer reports
    Current Opinion in Oncology
    Breast Cancer: Targets and Therapy
    Cancer Research and Treatment
    Cancer Treatment and Research Communications
    Asia-Pacific Journal Of Clinical Oncology
    ONCOLOGY